Headquartered in San Diego, CA Fiscal year ends December NASDAQ: JANX januxrx.com
Janux Therapeutics is a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies using its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) technology platforms. The company's lead clinical candidate, JANX007, is a PSMA-targeted TRACTr in Phase 1b trials for metastatic castration-resistant prostate cancer (mCRPC). Janux is also advancing JANX014, a double-masked PSMA TRACTr in Phase 1 trials, and JANX013, a CD28 costimulatory TRACIr designed for combination therapy with JANX007. Beyond oncology, the company is developing JANX011, a CD19-targeted ARM in Phase 1 trials in healthy volunteers for potential treatment of autoimmune diseases. Janux generates collaboration revenue through partnership arrangements and continues to build additional TRACTr, TRACIr, and ARM programs for future development. Updated
Wall Street analysts reshuffled the deck on Monday with a wave of upgrades, downgrades, and fresh initiations spanning pharma giants, fast-casual chains, and streaming players. Find out which names got bullish bets…
Pre-Market Stock Futures: The futures are trading flat after a stellar day across Wall Street, with all major indices finishing deep in positive territory. Traders cited an improving outlook for the Iran…
Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%. These pre-revenue or early-revenue firms carry significant risk, but their…
Janux Therapeutics is a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies using its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) technology platforms.
The Wall Street consensus 12-month price target for JANX is $36.24.
